2-tributylstannanyl-thieno[3,2-c]pyridine | 1416853-34-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并吡啶类
• 英文名称: 2-tributylstannanyl-thieno[3,2-c]pyridine
• 英文别名: 2-(tributylstannyl)thieno[3,2-c]pyridine；2-(Tributylstannyl)thieno[3,2-c]pyridine；tributyl(thieno[3,2-c]pyridin-2-yl)stannane
• CAS: 1416853-34-3
• 化学式: C₁₉H₃₁NSSn
• 分子量: 424.238
• InChiKey: YVCYCRJJHQIRRQ-UHFFFAOYSA-N

物化性质

• 沸点：
  452.4±48.0 °C(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.35
• 重原子数：
  22
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.63
• 拓扑面积：
  41.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-tributylstannanyl-thieno[3,2-c]pyridine 在 盐酸 、 copper(l) iodide 、 四(三苯基膦)钯 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 3.0h， 生成 6-(6-methylpyridin-2-yl)-5-{thieno[3,2-c]pyridin-2-yl}-1H,2H,3H-imidazo[1,2-a][1,3]diazole-2-carboxylic acid bishydrochloride
  参考文献：
  名称：

  [EN] IMIDAZOLE DERIVATIVES AS ALK5 INHIBITORS
  [FR] DÉRIVÉS D'IMIDAZOLE EN TANT QU'INHIBITEURS D'ALK5

  摘要：

  The present invention relates to compounds inhibiting the transforming growth factor β (TGF β) type I receptor (ALK5) (hereinafter ALK5 inhibitors), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of many diseases, disorders, or conditions associated with ALK5 signaling pathway.

  公开号：

  WO2023208986A1
• 作为产物：
  描述：

  噻吩并[3,2-c]吡啶 、 三丁基氯化锡 在 正丁基锂 、 四甲基乙二胺 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 以88 %的产率得到2-tributylstannanyl-thieno[3,2-c]pyridine
  参考文献：
  名称：

  [EN] IMIDAZOLE DERIVATIVES AS ALK5 INHIBITORS
  [FR] DÉRIVÉS D'IMIDAZOLE EN TANT QU'INHIBITEURS D'ALK5

  摘要：

  The present invention relates to compounds inhibiting the transforming growth factor β (TGF β) type I receptor (ALK5) (hereinafter ALK5 inhibitors), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of many diseases, disorders, or conditions associated with ALK5 signaling pathway.

  公开号：

  WO2023208986A1

文献信息

• 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS ALK5 AND/OR ALK4 INHIBITORS
  申请人：LEE Ju Young

  公开号：US20130018052A1

  公开（公告）日：2013-01-17

  The present invention provides a novel 2-pyridyl substituted imidazole derivative, or a pharmaceutically acceptable salt or solvate thereof, which selectively inhibits the transforming growth factor-β (TGF-β) type I receptor (ALK5) and/or the activin type I receptor (ALK4); a pharmaceutical composition comprising same as an active ingredient; and a use of the 2-pyridyl substituted imidazole derivative for the manufacture of a medicament for preventing or treating a disease mediated by ALK5 and/or ALK4 receptors in a mammal.

  本发明提供了一种新型的2-吡啶基取代咪唑衍生物，或其药学上可接受的盐或溶剂，该衍生物选择性地抑制转化生长因子-β（TGF-β）类型I受体（ALK5）和/或活化素类型I受体（ALK4）；一种包含其作为活性成分的制药组合物；以及使用该2-吡啶基取代咪唑衍生物制造哺乳动物ALK5和/或ALK4受体介导的疾病的药物的用途。
• Substituted 6-aza-isoindolin-1-one derivatives
  申请人：Kono Mitsunori

  公开号：US09056873B2

  公开（公告）日：2015-06-16

  Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein G, p, R1, R2, R3a, R4, and R5 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, cancer, and other disorders, diseases, and conditions for which inhibition of SYK is indicated.

  本发明涉及公式1的化合物及其药学上可接受的盐，其中G、p、R1、R2、R3a、R4和R5在说明书中有定义。本发明还涉及制备公式1的化合物的材料和方法，包括含有它们的制药组合物，以及它们用于治疗涉及免疫系统和炎症的紊乱、疾病和病况，包括类风湿性关节炎、癌症和其他需要抑制SYK的紊乱、疾病和病况。
• SUBSTITUTED 6-AZA-ISOINDOLIN-1-ONE DERIVATIVES
  申请人：Adams Mark E.

  公开号：US20140206680A1

  公开（公告）日：2014-07-24

  Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein G, p, R 1 , R 2 , R 3a , R 4 , and R 5 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, cancer, and other disorders, diseases, and conditions for which inhibition of SYK is indicated.

  本发明涉及公式1的化合物及其药学上可接受的盐，其中G、p、R1、R2、R3a、R4和R5在说明书中有定义。本发明还涉及制备公式1化合物的材料和方法，包括含有它们的制药组合物，以及它们用于治疗涉及免疫系统和炎症的紊乱、疾病和状况，包括类风湿性关节炎、癌症和其他需要抑制SYK的紊乱、疾病和状况。
• [EN] 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS ALK5 AND/OR ALK4 INHIBITORS<br/>[FR] 2-PYRIDYLIMIDAZOLES SUBSTITUÉS UTILISÉS COMME INHIBITEURS D'ALK5 ET/OU D'ALK4
  申请人：SK CHEMICALS CO LTD

  公开号：WO2013009140A3

  公开（公告）日：2013-04-11
• [EN] IMIDAZOLE DERIVATIVES AS ALK5 INHIBITORS<br/>[FR] DÉRIVÉS D'IMIDAZOLE EN TANT QU'INHIBITEURS D'ALK5
  申请人：[en]CHIESI FARMACEUTICI S.P.A.

  公开号：WO2023208986A1

  公开（公告）日：2023-11-02

  The present invention relates to compounds inhibiting the transforming growth factor β (TGF β) type I receptor (ALK5) (hereinafter ALK5 inhibitors), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of many diseases, disorders, or conditions associated with ALK5 signaling pathway.